Q2 2026 DaVita Inc Earnings Call Transcript
Key Points
- DaVita Inc (DVA) reported another positive quarter with adjusted operating income of $579 million and adjusted EPS of $4.02, in line with expectations.
- Treatment volume growth accelerated slightly faster than expected, driven by continued improvements in mortality, leading to increased confidence in achieving near the top end of the 25-50 basis points growth guidance.
- The transition of phosphate binders into the Medicare bundle has been successful, reducing reliance on less effective OTC options and improving patient access to clinically preferred therapies.
- DaVita Inc (DVA) has secured supply for expanded HD dialyzers, which are compatible with existing machines, allowing for broad deployment without significant capital investment and potentially improving patient outcomes.
- The company reaffirmed its full-year 2026 guidance for adjusted operating income and adjusted EPS, reflecting stable financial performance and strategic execution.
- DaVita Inc (DVA) continues to return capital to shareholders, repurchasing 2.2 million shares in Q2 and maintaining a consistent buyback program, with leverage within its target range.
- The minority investment in Elara Caring provides an opportunity to expand integrated care services, potentially enhancing patient care and creating new revenue streams.
- Revenue per treatment declined sequentially by approximately $2, reflecting lower commercial mix from declining ACA enrollment and lower phosphate binder revenue, with expectations of slightly negative RPT growth in the second half of 2026.
- The proposed 2027 ESRD payment update tracks below industry cost trends, potentially pressuring margins despite ongoing feedback to CMS.
- Patient care costs per treatment grew more than 3% year-to-date, above the expected range, though deceleration is anticipated in the back half of the year.
- The company experienced higher-than-expected miss treatments and fewer admits from closed Fresenius clinics, which partially offset volume gains.
- Commercial mix is expected to decline further, with a $40 million headwind in 2026 and an additional $70 million impact in 2027, driven by lower new patient mix from ACA subsidy expirations.
- The financial impact of deploying expanded HD technology is not expected to be significant until 2028, when mortality benefits may begin to materialize, delaying potential economic upside.
- G&A costs increased by $11 million sequentially, contributing to elevated cost per treatment growth in the first half of the year.
Good evening. My name is Michelle, and I will be your conference facilitator today. At this time, I would like to welcome everyone to the DaVita second quarter 2026 earnings call. (Operator Instructions)
Mr. Lisin, you may begin your conference.
Thank you, and welcome to our second quarter conference call. We appreciate your continued interest in our company. I'm Nic Eliason, Group Vice President of Investor Relations. And joining me today are Javier Rodriguez, our CEO; and Joel Ackerman, our CFO. Please note that during this call, we may make forward-looking statements within the meaning of the federal securities laws.
All of these statements are subject to known and unknown risks and uncertainties that could cause the actual results to differ materially from those described in the forward-looking statements. For further details concerning these risks and uncertainties, please refer to our second quarter earnings press release and our SEC filings, including our most recent
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
